Hydrocodone Acetaminophen
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D2-25-D-0007
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents2
The Defense Logistics Agency (DLA) Troop Support has issued an award notice under procurement identifier SPE2D2-25-D-0007 for the supply of Hydrocodone Acetaminophen. This contract falls under the North American Industry Classification System (NAICS) code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is further classified by Product Service Code 6505, indicating a focus on drugs and biologicals.
The primary objective of this procurement is to ensure a reliable supply of Hydrocodone Acetaminophen, a critical pharmaceutical product, to support federal requirements. The scope of the contract encompasses the manufacturing and delivery of this medication to designated locations within New York, United States. The intended outcome is to maintain the availability of essential pharmaceutical preparations for federal use, supporting the health and operational readiness of personnel.
Key requirements for this contract include compliance with all relevant pharmaceutical manufacturing standards and regulations, as well as the ability to deliver the specified product to the place of performance in New York. Contractors are expected to provide Hydrocodone Acetaminophen in accordance with the specifications outlined by DLA Troop Support, ensuring quality, safety, and timely delivery throughout the contract lifecycle.
The contracting entity for this award is DLA Troop Support, a federal office responsible for the procurement and distribution of medical supplies and pharmaceuticals. Interested parties or current contractors may direct inquiries to the primary contact, Christopher Newman ([email protected], 215-737-2905), or the secondary contact, Jason Wray ([email protected], 215-737-0614), for further information regarding contract administration or performance requirements.
This award notice is currently active and was posted on February 20, 2025. Additional details, including attachments related to the opportunity, can be accessed via the official SAM.gov listing at https://sam.gov/opp/cadf08f59bec439584fa982e83919981/view.
Contractors evaluating this opportunity should note that the core elements—pharmaceutical manufacturing under NAICS 325412, delivery to New York, and compliance with federal standards—will remain consistent throughout the duration of the contract. No set-aside requirements or special considerations are specified in the provided information. This opportunity is best suited for organizations with established capabilities in pharmaceutical preparation and distribution, particularly those experienced in supplying controlled substances to federal entities.